ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2010
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Identifying biomarkers associated with tumor growth rate: a longitudinal preoperative magnetic resonance imaging follow-up of low-grade gliomas.Annals of translational medicine · 2022Article
- Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity.Oncotarget · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChildhood glioblastoma multiforme (GBM) is uncommon, accounting for 7.2% of the central nervous system tumors in childhood. Their clinical behaviors are almost as aggressive as those in adults, and the 5-year overall survival rate is poor. CASE REPORT: We describe a case of a 13-year-old boy with GBM. Fourteen months after surgical resection followed by radiotherapy and temozolomide chemotherapy, the patient showed local recurrence. No response to subsequent bevacizumab treatment was observed. To determine correlations of molecular alterations with clinical outcomes in this case, we examined the expressions of Ki-67, MMP-9, MGMT, VEGF, Ras, and p-AKT using biopsies before and after recurrence. DISCUSSION: Childhood glioblastomas show a distinct biological behavior and probably a different molecular pathogenesis in comparison to the adult ones. Understanding the molecular mechanisms responsible for the formation and progression of the tumors is critical for identification of novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.